Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From tech.aseancoverage.com

China accuses US of trying to block its tech development

Feb 18, 2019

BEIJING — China's government on Monday accused the United States of trying to block its industrial development by alleging that Chinese mobile network gear poses a cybersecurity threat to countries rolling out new internet systems. And in a potential blow to the U.S.'s effort to rally its allies on the issue, British media reported that the country's intelligence agencies have found it's possible to limit the security risks of using Chinese equipment in so-called 5G networks. The U.S. argues that Beijing might use Chinese tech companies to gather intelligence about foreign countries. The Trump administration has been putting pressure on...

For sake of pupils' pupils, China to ban homework on apps

Feb 18, 2019

BEIJING — An eastern Chinese province plans to ban teachers from assigning homework to be completed on cellphone apps as part of efforts to preserve students' eyesight. Zhejiang province issued a draft regulation last week and is seeking public comment. It is one of several provinces considering such measures. Along with barring app-based homework assignments, the Zhejiang regulation would limit the use of electronic devices to 30 percent of total teaching time and encourage the issuing of paper homework to be completed by hand. Soaring rates of nearsightedness are blamed partly on screen usage. While China's overall rate of myopia...

Unicorns are real: Tech baffles Indonesian candidate

Feb 18, 2019

JAKARTA, Indonesia — Indonesia's presidential candidates debated some of the most pressing issues facing the world's third-largest democracy: dilapidated infrastructure, struggling farmers, forest fires — and unicorns. When President Joko Widodo, who is seeking a second term, asked challenger Prabowo Subianto about his policies for supporting unicorns — tech start-up companies worth at least $1 billion — a look of bafflement passed across the former general's face. Wondering aloud, he replied: "What are unicorns? You mean those online things?" Widodo sagely nodded in the affirmative before Subianto explained he supports online businesses. Subianto was probably not alone in his ignorance,...

China, US announce more trade talks next week

Feb 18, 2019

BEIJING — With a deadline looming, U.S. and Chinese negotiators will hold more talks in Washington next week aimed at ending a battle over Beijing's technology ambitions. The announcement Friday came after U.S. Trade Representative Robert Lighthizer told Chinese President Xi Jinping that negotiators "made headway" in talks this week in Beijing. They had been the last scheduled before planned U.S. penalties on $200 billion of Chinese products are due to take effect March 2. The United States "hopes to see additional progress," a White House statement said. It gave no indication whether President Donald Trump would extend the deadline....

The Latest: China's Xinhua: US trade talks for next week

Feb 18, 2019

BEIJING — The Latest on China-U.S. trade talks in Beijing (all times local): 6:40 p.m. An official Chinese news agency says U.S. and Chinese negotiators will meet next week in Washington for talks on a technology dispute ahead of a March 2 deadline for a planned American tariff hike. The Xinhua News Agency's announcement followed two days of talks in Beijing that had been the last scheduled meeting before the March 2 deadline. President Donald Trump's economic adviser said earlier he had yet to decide whether to escalate the dispute by going ahead with the penalties on $200 billion of...

AseanCoverage is a next-gen news site focusing exclusively on online news from South East Asia.

Contact us: sales[at]aseancoverage.com